The ENAR Therapy System device is a hand-held, battery operated, therapeutic medical device, for both persona and therapist use. AUST 147761 The ENAR or Electro-Neuro- Adaptive-Regulator, delivers non-invasive, non-toxic, interactively therapeutic, computer modulated, electro-energetic stimulation, onto and through the skin. It has two university research studies to its credit showing results that are both significant and sustained with many chronic painful problems.
How does ENAR work?
The ENAR is used to find and treat ‘asymmetries’. Asymmetries are differences, tell-tale signs of problems that can be detected when using the ENAR device on the skin. The ENAR’s interactive therapeutic stimulation process fuses ‘Bio-feed-back’ and ‘Bio-feed-forward’ in a ‘real time’ dialogue with the nervous system to prompt any faulty or unfavourable areas to return to a naturally healthy state. Ultimately there are at least two common explanations for the ENAR’s therapeutic effectiveness. The Bio-Chemical explanation suggests the ENAR prompts the release of neuro–peptides, generating a cascade of natural healing hormones. The Bio-Energetic view suggests the ENAR clears and regulates neuro-energy-pathways and so restores the flow of energy and information, and this facilitates both the pain relief and healing.
What can the ENAR achieve?
Australian health practitioners and members of the public are using ENAR devices to great effect. They find that the ENAR can have a profound effect on both chronic and acute painful conditions and injuries that may not respond to other forms of treatment. The ENAR is also used to locate hidden, referred and primary treatment points in ways that might not be evident by other means.
A Macquarie University randomised control trial using ENAR versus conventional TENS has been conducted in Sydney and this showed ‘dramatic and sustained results’ with chronic pain relief, disability reduction, functional improvements and general health restoration. Full research report available here.
An RMIT University patient surveillance study involving 481 cases showed an average reduction in chronic pain of 70%. See full report available here